HomeCompareCRGX vs EQR

CRGX vs EQR: Dividend Comparison 2026

CRGX yields 44.74% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRGX wins by $251.4K in total portfolio value
10 years
CRGX
CRGX
● Live price
44.74%
Share price
$4.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$299.2K
Annual income
$55,447.86
Full CRGX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — CRGX vs EQR

📍 CRGX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRGXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRGX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRGX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRGX
Annual income on $10K today (after 15% tax)
$3,803.13/yr
After 10yr DRIP, annual income (after tax)
$47,130.68/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, CRGX beats the other by $42,476.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRGX + EQR for your $10,000?

CRGX: 50%EQR: 50%
100% EQR50/50100% CRGX
Portfolio after 10yr
$173.5K
Annual income
$30,461.73/yr
Blended yield
17.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CRGX
Analyst Ratings
6
Hold
1
Sell
Consensus: Hold
Price Target
$23.00
+414.5% upside vs current
Range: $7.00 — $34.00
Altman Z
3.1
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRGX buys
0
EQR buys
0
No recent congressional trades found for CRGX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRGXEQR
Forward yield44.74%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$299.2K$47.8K
Annual income after 10y$55,447.86$5,475.61
Total dividends collected$232.3K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$23.00$70.35

Year-by-year: CRGX vs EQR ($10,000, DRIP)

YearCRGX PortfolioCRGX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$15,174$4,474.27$11,380$679.82+$3.8KCRGX
2$22,582$6,345.22$13,014$837.25+$9.6KCRGX
3$32,987$8,824.93$14,961$1,036.20+$18.0KCRGX
4$47,345$12,048.10$17,297$1,289.22+$30.0KCRGX
5$66,819$16,160.60$20,121$1,613.15+$46.7KCRGX
6$92,813$21,315.98$23,561$2,030.84+$69.3KCRGX
7$126,981$27,671.12$27,783$2,573.54+$99.2KCRGX
8$171,251$35,381.27$33,013$3,284.39+$138.2KCRGX
9$227,833$44,594.79$39,547$4,223.51+$188.3KCRGX
10$299,229$55,447.86$47,791$5,475.61+$251.4KCRGX

CRGX vs EQR: Complete Analysis 2026

CRGXStock

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Full CRGX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CRGX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRGX vs SCHDCRGX vs JEPICRGX vs OCRGX vs KOCRGX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.